New blood marker duo could spot leukemia earlier
NCT ID NCT07740603
First seen Jul 31, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study investigates whether measuring two proteins, CD38 and CD56, on white blood cells called neutrophils can help diagnose chronic myeloid leukemia (CML). Researchers will compare the levels of these markers in 200 people with CML to see if a high percentage is a reliable sign of the disease. If the markers prove distinctive, they could become a new diagnostic tool for this blood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Diagnostic test measuring CD38 and CD56 expression on neutrophils
- What this could lead to
- If successful, this could lead to a new, simpler diagnostic tool for chronic myeloid leukemia, potentially improving early detection and monitoring.
- What could go wrong
- This is an early-stage study, and the marker may not be specific enough to distinguish CML from other conditions. Further validation is needed before clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug help leukemia patients stay off cancer pills?
- Personalized exercise shows promise for fatigue in rare blood cancers
- Engineered donor cells aim to beat blood cancer without severe side effects
- Could dead donors provide Life-Saving bone marrow?
- Can patients stop Anti-Rejection drugs sooner after transplant?
- Could a malaria drug boost leukemia treatment?